Evotec Stock LIQUIDNET SYSTEMS

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Delayed LIQUIDNET SYSTEMS 11:16:39 2018-05-17 am EDT 5-day change 1st Jan Change
13 EUR +8.33% Intraday chart for Evotec -.--% -.--%
Sales 2024 * 881M 939M Sales 2025 * 1.05B 1.12B Capitalization 1.73B 1.84B
Net income 2024 * 10M 10.66M Net income 2025 * 73M 77.8M EV / Sales 2024 * 1.78 x
Net cash position 2024 * 161M 172M Net cash position 2025 * 166M 177M EV / Sales 2025 * 1.48 x
P/E ratio 2024 *
71.2 x
P/E ratio 2025 *
17.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 19-06-18
Director of Finance/CFO 51 23-02-06
Chief Operating Officer 54 12-04-30
Members of the board TitleAgeSince
Chief Executive Officer 61 19-06-18
Director/Board Member 56 19-06-18
Chairman 63 14-06-16
More insiders
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.74 EUR
Average target price
24.2 EUR
Spread / Average Target
+148.46%
Consensus